Pfizer Financial Statements
NYSE: PFEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:01 PM ET · Delayed 15 min
Pfizer revenue and earnings
In fiscal 2025, Pfizer generated $62.58 billion in revenue, down 1.6% from fiscal 2024, its first annual decline since 2023. Net income was $7.77 billion (-3.2% year over year), for a net margin of 12.4% versus a median of 22.0% in the prior 5 years. Gross margin was 74.3% (up from 71.9%).
Diluted earnings per share came in at $1.36, down from $1.41. Over the last 5 fiscal years, PFE's revenue has grown at a 8.5% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Pfizer income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 62.58B | 63.63B | 59.55B | 101.17B | 81.29B | 41.65B | 40.91B | 40.83B | 52.55B | 52.82B |
| Revenue growth (YoY) | -1.65% | +6.84% | -41.14% | +24.46% | +95.16% | +1.82% | +0.20% | -22.31% | -0.53% | +8.13% |
| Cost of Revenue | 16.07B | 17.85B | 24.95B | 34.34B | 30.82B | 8.48B | 8.05B | 8.99B | 11.23B | 12.32B |
| Gross Profit | 46.51B | 45.78B | 34.60B | 66.83B | 50.47B | 33.17B | 32.85B | 31.84B | 41.32B | 40.50B |
| Research & Development | 10.44B | 10.82B | 10.68B | 11.43B | 10.36B | 8.71B | 8.38B | 7.76B | 7.68B | 7.89B |
| Selling, General & Admin | 13.79B | 14.73B | 14.77B | 13.68B | 12.70B | 11.60B | 12.73B | 12.61B | 14.80B | 14.84B |
| Interest Expense | 2.67B | 3.09B | 2.21B | 1.24B | 1.29B | 1.45B | 1.57B | 1.32B | 1.27B | 1.19B |
| Other Income (Expense) | -6.72B | -4.39B | -222.00M | -1.06B | 4.88B | -1.21B | -3.50B | -2.08B | -1.42B | -3.79B |
| Pretax Income | 7.52B | 8.02B | 1.06B | 34.73B | 24.31B | 7.04B | 11.32B | 3.59B | 12.30B | 8.35B |
| Income Tax | -266.00M | -28.00M | -1.11B | 3.33B | 1.85B | 370.00M | 583.00M | -266.00M | -9.05B | 1.12B |
| Net Income | 7.77B | 8.03B | 2.12B | 31.37B | 21.98B | 9.16B | 16.03B | 11.15B | 21.31B | 7.21B |
| Net Income growth (YoY) | -3.24% | +279.00% | -93.25% | +42.74% | +139.97% | -42.85% | +43.69% | -47.66% | +195.33% | +3.66% |
| EPS (Basic) | 1.37 | 1.42 | 0.38 | 5.59 | 3.92 | 1.65 | 2.88 | 1.90 | 3.57 | 1.18 |
| EPS (Diluted) | 1.36 | 1.41 | 0.37 | 5.47 | 3.85 | 1.63 | 2.82 | 1.87 | 3.52 | 1.17 |
| Shares Outstanding (Basic) | 5.68B | 5.66B | 5.64B | 5.61B | 5.60B | 5.55B | 5.57B | 5.87B | 5.97B | 6.09B |
| Shares Outstanding (Diluted) | 5.71B | 5.70B | 5.71B | 5.73B | 5.71B | 5.63B | 5.67B | 5.98B | 6.06B | 6.16B |
| Gross Margin | 74.33% | 71.94% | 58.10% | 66.05% | 62.08% | 79.63% | 80.31% | 77.99% | 78.63% | 76.67% |
| Net Margin | 12.42% | 12.62% | 3.56% | 31.01% | 27.04% | 21.99% | 39.18% | 27.32% | 40.55% | 13.66% |
This table shows 10 annual periods of Pfizer's income statement, from FY 2025 back to FY 2016, across 16 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow PFE's reporting calendar. What is a income statement?